Global X Genomics & Biotechnology ETF
GNOM
40 hedge funds and large institutions have $13.9M invested in Global X Genomics & Biotechnology ETF in 2026 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 5 closing their positions.
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
0% more funds holding
Funds holding: 40 → 40 (0)
1.03% less ownership
Funds ownership: 28.79% → 27.77% (-1%)
6% less capital invested
Capital invested by funds: $14.8M → $13.9M (-$877K)
25% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$2.24M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$424K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$286K |
| 4 |
WMP
Wealth Management Partners
Tucson,
Arizona
|
+$258K |
| 5 |
Jane Street
New York
|
+$158K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FTUS
Flow Traders U.S.
New York
|
-$880K |
| 2 |
IWM
IHT Wealth Management
Chicago,
Illinois
|
-$822K |
| 3 |
Two Sigma Investments
New York
|
-$797K |
| 4 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
-$510K |
| 5 |
ACS
Archford Capital Strategies
Swansea,
Illinois
|
-$281K |
GNOM Hedge Fund Activity: Q1 2026 in Review
40 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Global X Genomics & Biotechnology ETF (GNOM) for Q1 2026, worth a combined $13.9M — down 5.9% from $14.8M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new GNOM positions and 5 closed out — a net gain of 1 holder — while 9 added to existing stakes and 12 trimmed.
The largest buyer was Bank of America, adding an estimated $2.24M. The largest seller was Flow Traders U.S., exiting entirely with an estimated $880K sold.
- 40 institutional investors held Global X Genomics & Biotechnology ETF (GNOM) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $13.9M of Global X Genomics & Biotechnology ETF stock for Q1 2026, down 5.9% quarter-over-quarter.
- 6 funds opened new Global X Genomics & Biotechnology ETF positions in Q1 2026 and 5 closed out, a net change of +1 holder.
- The largest Global X Genomics & Biotechnology ETF buyer in Q1 2026 was Bank of America, an estimated $2.24M added.
- The largest Global X Genomics & Biotechnology ETF seller in Q1 2026 was Flow Traders U.S., an estimated $880K sold.
Based on aggregated 13F filings for Q1 2026.